Close Menu

National Venture Capital Association

Silicon Valley remained the top US cluster with $210 million in first-quarter venture capital, down a little over 16 percent from the $251 million racked up a year earlier. New England's $149 million in biopharma VC marked a nearly 32 percent fall-off.

Two top BioMed officials told investors that stronger activity at two nearly-completed Northeast projects and a stash of cash will enable it to continue paying customary dividends, though conceded a slowdown in Bay Area leasing.

Assemblymember Mark Weprin’s bill would allow New York City to award up to $250,000 in tax credits over four years to life-sci companies that build new facilities or create jobs in the Big Apple.

The declines also showed that eight of 23 states with biotech VC activity in the final three months of 2008 recorded decreased funding over the year-ago period, with the steepest slides recorded in established biocluster states.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.